Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Assets (2020 - 2025)

Historic Assets for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $114.1 million.

  • Burning Rock Biotech's Assets fell 1870.39% to $114.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $114.1 million, marking a year-over-year decrease of 1870.39%. This contributed to the annual value of $121.3 million for FY2024, which is 1719.94% down from last year.
  • Per Burning Rock Biotech's latest filing, its Assets stood at $114.1 million for Q3 2025, which was down 1870.39% from $115.2 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Assets registered a high of $659.4 million during Q4 2021, and its lowest value of $114.1 million during Q3 2025.
  • Its 5-year average for Assets is $237.1 million, with a median of $183.5 million in 2023.
  • Per our database at Business Quant, Burning Rock Biotech's Assets surged by 6157.73% in 2021 and then crashed by 6509.76% in 2022.
  • Quarter analysis of 5 years shows Burning Rock Biotech's Assets stood at $659.4 million in 2021, then crashed by 65.1% to $230.2 million in 2022, then tumbled by 36.36% to $146.5 million in 2023, then dropped by 17.2% to $121.3 million in 2024, then decreased by 5.94% to $114.1 million in 2025.
  • Its Assets was $114.1 million in Q3 2025, compared to $115.2 million in Q2 2025 and $117.8 million in Q1 2025.